News
RARE
35.67
+0.76%
0.27
Ultragenyx to Present at Piper Sandler Healthcare Conference
NOVATO, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announc...
GlobeNewswire · 11/22 21:01
Ultragenyx Pharmaceutical (NASDAQ:RARE) shareholders have endured a 55% loss from investing in the stock a year ago
The nature of investing is that you win some, and you lose some. Unfortunately, shareholders of Ultragenyx...
Simply Wall St. · 11/21 13:42
Ultragenyx Pharmaceutical Chief Financial Officer Mardi Dier to Depart for Private Biopharma Company
Ultragenyx Pharmaceutical Chief Financial Officer Mardi Dier to Depart for Private Biopharma Company
MT Newswires · 11/11 05:20
BRIEF-Ultragenyx Announces Departure Of Chief Financial Officer
Reuters · 11/10 21:36
Ultragenyx Pharmaceutical CFO Mardi Dier to step down
Seekingalpha · 11/10 21:28
Goldman Sachs Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $55
Benzinga · 11/04 15:05
Where Ultragenyx Pharmaceutical Stands With Analysts
Benzinga · 11/03 21:09
Morgan Stanley Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $100
Benzinga · 11/03 13:22
SVB Leerink Maintains Outperform on Ultragenyx Pharmaceutical, Lowers Price Target to $108
Benzinga · 11/03 13:18
Credit Suisse Maintains Outperform on Ultragenyx Pharmaceutical, Lowers Price Target to $96
Benzinga · 11/03 13:00
Baird Upgrades Ultragenyx Pharmaceutical to Outperform, Lowers Price Target to $50
Benzinga · 11/03 12:12
--Credit Suisse Adjusts Ultragenyx Pharmaceutical's Price Target to $96 From $105, Keeps Outperform Rating
--Credit Suisse Adjusts Ultragenyx Pharmaceutical's Price Target to $96 From $105, Keeps Outperform Rating
MT Newswires · 11/03 11:27
--Baird Upgrades Ultragenyx Pharmaceutical to Outperform From Neutral, Adjusts Price Target to $50 From $63
--Baird Upgrades Ultragenyx Pharmaceutical to Outperform From Neutral, Adjusts Price Target to $50 From $63
MT Newswires · 11/03 10:49
--Wedbush Lowers Ultragenyx Pharmaceutical's PT to $49 From $51, Says Waiting for Additional Visibility Into Clinical Programs; Keeps Neutral Rating
--Wedbush Lowers Ultragenyx Pharmaceutical's PT to $49 From $51, Says Waiting for Additional Visibility Into Clinical Programs; Keeps Neutral Rating
MT Newswires · 11/03 08:45
Ultragenyx Pharmaceutical GAAP EPS of -$3.50 misses by $1.66, revenue of $90.7M misses by $5M
Seekingalpha · 11/02 20:49
Ultragenyx Pharmaceutical Q3 EPS $(2.43) Misses $(1.81) Estimate, Sales $90.70M Miss $96.20M Estimate
Benzinga · 11/02 20:35
-- Earnings Flash (RARE) ULTRAGENYX PHARMACEUTICAL Reports Q3 Revenue $90.7M
-- Earnings Flash (RARE) ULTRAGENYX PHARMACEUTICAL Reports Q3 Revenue $90.7M
MT Newswires · 11/02 16:25
Ultragenyx to Host Conference Call for Third Quarter 2022 Financial Results and Corporate Update
NOVATO, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announce...
GlobeNewswire · 10/27 20:01
Earnings Preview: Ultragenyx (RARE) Q3 Earnings Expected to Decline
Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 10/25 14:01
Mereo BioPharma to shed 40% of workforce as part of cost-cutting plan
Seekingalpha · 10/18 11:22
More
Webull provides a variety of real-time RARE stock news. You can receive the latest news about Ultragenyx Pharm through multiple platforms. This information may help you make smarter investment decisions.
About RARE
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company, which is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. The Company’s therapies and clinical-stage pipeline consist of four product categories, such as biologics, small molecules, gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) is for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO); Mepsevii (vestronidase alfa) is for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome; Dojolvi (triheptanoin) is for the treatment of long-chain fatty acid oxidation disorders or LC-FAOD, and Evkeeza (evinacumab) is for the treatment of homozygous familial hypercholesterolemia (HoFH). The Company' clinical product candidates include DTX401, DTX301, UX143, GTX-102, UX701 and UX053.